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Rat hepatocyte protein kinase was activated by in- addition to long-term desensitization effects, there may exist
cubating the cells with various cAMP analogs. Boiled feedback mechanisms for acutely dampening the hormonal
extracts were then prepared and Sephadex
G-25 chro- effect on cAMP levels. A convenient route of such control
matography was carried out. The
G-25 procedure sep- would be through activation of CAMP-dependent protein kiarated the analogs from
cAMP since the resin had the nase, which thus far has been the only receptor for cAMP
unexpected property of binding
cyclic nucleotideswith shown to be present in higher eukaryotes. It would bedifficult
differing affinities. Separation was necessary because to study a dampening effect of kinase activation on cAMP
the analogs wouldotherwise interfere with the sensi- levels by the use of hormones. However, such a study can be
tive protein kinase activation method developed for
accomplished by using cAMP analogs to bypass the hormoneassay of CAMP. The cAMP analogs, but not S‘-AMP, adenylate cyclase steps. Analogs of cAMP are known to enter
lowered basalcAMP by50-70%.The effect was rapid, cells and specifically activate CAMP-dependentprotein kinase
analog concentration-dependent, and occurred parallel
(9). This report presents a simple method for carrying out
with phosphorylase activation, suggesting thatthe
purification
and assay of cAMP after treatment of hepatocAMP analogs act through CAMP-dependent protein
kinase activation. A cAMP analog completely blocked cytes with cAMP analogs. Using phosphorylase activation as
the cAMP elevationproduced byrelatively low concen- an indicator of protein kinase activation, it is shown that
intracellular stimulationof the kinase dampens the hormonal
trations of glucagon, but did not block the phosphorylase response, indicating that thecAMP analog substi- elevation of cAMP in hepatocytes.
of protein
tutes forcAMP as the intracellular activator
METHODS
kinase. One implication of the results is that elevation
of cAMP andprotein kinase activity by hormones has
Preparation and Incubation of Hepatocytes-Hepatocytes from
a negative feedback effect on the cellularcAMP level. male Sprague-Dawley rats (200-250 g of body weight) were prepared
~

~~

~

~

There are present in biological systems certain processes
which amplify hormonal effects. A few molecules of glucagon,
for example, can cause thousands of glucose molecules to be
produced in liver. However, in order for such amplification to
be effective, each step involved must not be excessive. For
example, changes in cellular cAMP levels usually occur within
a very narrow concentration range, physiological processes
being maximally stimulated by increases in cAMP of only 23-fold (1-3). If the cAMP concentration were to be elevated
to very high levels relative to thephysiological range, reversal
of the stimulatory processes would be difficult. In order that
such excessive changes do not occur, “leak” systems are also
present for dampening the amplification (4). Phosphodiesterases and protein phosphatases are two types of leak systems
in the reactions of the cAMP cascade. These enzyme activities
are increased because of increases in substrate levels. They
serve, on the one hand, to dampen the increase in CAMP,
and, onthe otherhand, to dephosphorylate, or deactivate, the
protein phosphorylation reactions. Cells have also evolved
mechanisms to “desensitize,” “down-regulate,” or produce
“refractoriness” after chronic exposure to hormones which
elevate cAMP (1,5-8). These in some cases involve uncoupling of the hormone receptor from the adenylate cyclase. In
* This work was supported in part by Research Grant AM 15988
from the National Institutes of Health. The costs of publication of
this article were defrayed in part by the payment of page charges.
This article must therefore be hereby marked “aduertisement” in
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as previously described (10). Cyclic AMP analogs were added to cell
suspensions (-50 mg of cells/ml) in 25-ml Erlenmeyer flasks a t 37 “C
which were continuously gassed with 02:COz (191). At various times
aliquots wereremoved for the measurement of phosphorylase or
CAMP.All cAMP analog stock solutions were 100-fold more concentrated than thedesired final concentration in the hepatocyte suspensions.
Preparation of Extracts and Assay of Phosphorylase-At the endof
the hepatocyte incubations, 500-pl aliquots of the cell suspensions
were removed, immediately frozen in liquid nitrogen, and stored at
-20 “C. The pellets were thawed at room temperature for 10 min.
One mlof homogenizing buffer containing 150 mM 8-glycerophosphate, 30 mM EDTA, 150 mM NaF, 600 mM sucrose, and 6.5 mg/ml
L-cysteine was added, and the suspension was homogenized for 10 s
using an Ultraturrex TissuemizeP. Homogenates were immediately
assayed for phosphorylase activity in the absence of 5’-AMP (10).
Preparation of Boiled Extracts for Sephadex (3-25Purification of
CAMP-Four ml of cell suspension was centrifuged at 500 X g, the
supernatant was removed, and the cell pellet was frozen in liquid
nitrogen and stored at -70 ‘C. Frozen cell pellets were removedfrom
-70 “C andthawed at room temperature for 3-5 min. One ml of icecold homogenizingbuffer (25 mM NH,HCOs, pH 7.8,l mM 3-isobutyl1-methylxanthine, and 20 mM EDTA) was added, and the suspension
was placed on ice. The partially thawed pellets were homogenized for
10 s using an Ultraturrex Tissuemizer@.The entire homogenate was
placed in a 1.5-ml microfhge tube and placed in a boiling water bath
for 5 min. The boiled homogenates were centrifuged for 7 min in a
Beckman Microfuge B. The boiled extract was carefully removed and
chilled on ice before purification of cAMP by Sephadex G-25 chromatography of 0.5-ml aliquots as described under “Results.”
Assay of CAMP-The type I CAMP-dependentprotein kinase used
for the assay was purified from rabbit skeletal muscle through the
DEAE-cellulose step (11). The enzyme was frozen and stored at
-70 “C in small aliquots which were thawed immediately before use
by hand-warming. Protein kinase assays were performed at different
times and temperatures as shown in Fig. 3. To 20 pl of reaction
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mixture containing 40 mM Tris-HC1, pH 7.4,0.1 mM 3-isobutyl-lmethylxanthine, 130 p~ heptapeptide (Kemptide),20 mM magnesium
acetate, and 0.2 mM [32P]ATP(-100 cpm/pmol) was added 60 pl of
fractions from the Sephadex G-25 chromatography or cAMP standards diluted in the same 50 mM NHIHC03, pH 7.8. Reactions were
initiated with 20 pl of enzyme diluted to 0.33 nM with 10 mM
potassium phosphate, pH 6.8, 1 mM EDTA, and 1 mg/ml bovine
serum albumin. After incubation, 50-p1 aliquots of the mixture were
spotted on phosphocellulose papers which were washed in 75 mM
phosphoric acid according to Roskoski (12).
In one experiment cAMP was also assayed by radioimmunoassay
(13-15).
Purification of CAMP Analogs-The cAMP analogs which were
used for cell incubations were first chromatographed on a 0.9 X 57cm Sephadex G-25 (superfine) column as described in the legend to
Fig. 1. The total volume (V,) of the G-25 was taken as the elution
volume of r3HlH20.
The
elution volume of a particular substancewas
.
denoted as V..
Materials-The
heDtaDeDtide substrate, Leu-Arg-Arg-Ala-SerLeuIGly, was from Peninsula Laboratories. Sephadex G-25 (superfine) and gel filtration columns were purchased from Pharmacia.
cAMP and cAMP analogs were from Sigma, and [3H]cAMPwas from
New England Nuclear. 8-pC1@S-cGMP1was synthesized by the
method of Miller et al. (16). [Y-~'P]ATPwas prepared by the method
of Walseth and Johnson (17). Glucagon was a gift from Eli Lilly.
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RESULTS

Sephadex G-25 Chromatography of Cyclic NucleotidesSince most cyclic nucleotide analogs are known to interfere
in biospecific assays or radioimmunoassays of cAMP (13-15,
18), it was necessary to devise a method for separating the
analog from cAMP before assay. Various nucleotides are
known to bind to Sephadex columns with different affinities
(19). Many have elution volumes (V,) greater than the total
volume (V,) of the columns. The Sephadex G-25 (superfine)
elution profiles for several cyclic nucleotides are shown in Fig.
1. Of the four nucleotides chromatographed, only N6-butyrylcAMP eluted at less than the totalvolume as determined by
[3H]H20elution. It can be seen that all three analogs were
clearly separated from cAMP at this temperature (20 "C). It
was found subsequently that even better separation could be
obtained at 4 "C. For example, cAMP and cGMP were poorly
separated at 20 "C, but were almost completely separated a t
4 "C. The elution volume of [3H]H20(V,)was not different
at thedifferent temperatures, but theV J V ,of cAMP changed
from 1.35 a t 20 "C to 1.62 at 4 "C. The relatively long column
(0.9 x 57 cm) used for the experiment of Fig. 1 allowed for
high resolution of cyclic nucleotides, but a shorter column
(0.9 x 14 cm) at 4 "C was sufficient to separate most of the
analogs and allowed for rapid (-2 h) processing of boiled
hepatocyte extracts. Chromatography of a boiled hepatocyte
extract on the short column at 4 "C is shown in Fig. 2. It can
be seen that 8-pCldS-cAMP separated well from CAMP. It
can also be seen that cAMP was separated from almost all of
the
absorbing material of the extract. The assayable
cAMP of the extract coeluted with the trace amount of [3H]
cAMP added to theextract. The small 3H peak preceding the
[3H]cAMP peak could represent [3H]H20,since the V, was
identical to that of [3H]H20chromatographed in a different
run. The method of Fig. 2 was adopted for almost all of the
experiments, although the longer column was necessary for
separating some analogs which had a V, nearly the same as
that of CAMP.
Assay of CAMP by Protein Kinase Activation-Because of
the dilution which resulted from the Sephadex chromatography, it was necessary to develop a sensitive assay for CAMP.
The use of protein kinase activation at 30 "C was reported
previously (20). It can be seen in Fig. 3 that the kinase was
I

a

The abbreviation used is: 8-pCl@S-,8-p-chlorophenylthio-.

ELUTIONVOLUME(ml1

FIG. 1. Chromatography of cAMP analogs on Sephadex G26.Samples (0.5 ml of 100 mM N'-butyryl-cAMP, 0.3 mM 8-pClgSCAMP,20 mM 8-Br-cAMP, or 0.1 ml of 1mM CAMP)were dissolved
in HzO and -60 mg of sucrose was added to each and dissolved. They
were then applied a t 20 "Cto a 0.9 X 57-cm Sephadex G-25 (superfine)
column which had been equilibrated in 50 mM NH4HC03, pH 7.8.
Collection was by gravity flow with 60 cmof hydrostatic pressure.
1.5-ml fractions were collected. N'-Butyryl-cAMP fractions were
diluted 700-fold and 8-Br-CAMPsamples were diluted 100-fold before
determining absorbance.
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FIG. 2. Chromatography of a crude hepatocyte extract on
Sephadex G-26.The hepatocyte extract was prepared as described

under "Methods." Ten pl of 1.8 X lo" M [3H]cAMP (80,000 cpm)
was added a t 4 "C to 0.5 ml of extract. Solid sucrose (-60 mg) was
then added and dissolved, and thesample was applied a t 4 "C to a 0.9
X 14-cm Sephadex G-25 (superfine) column equilibrated in 50 mM
NH4HC03,pH 7.8. One-ml fractions were collected by gravity flow
(50 cm of hydrostatic pressure). Fifty-pl aliquots were analyzed for
radioactivity. Sixty-pl aliquots were used for cAMP determination as
described under "Methods," and the Ezsowas measured spectrophotometrically. The elution of 60 p~ 8-pCl@S-cAMPwas determined in
a separatechromatographic run performed identically and theprofile
is shown for comparison. The presence of the extract did not significantly alter the elution of &pCl@S-cAMP(not shown).

much more sensitive to cAMP at 0 "C than athigher temperatures, presumably because the affinity of cAMP binding
increased. The K, obtained at 0 "C (5 nM) was 16 times lower
than that at 30 "C. In order to produce sufficient 32P-heptapeptide at lower temperatures, it was necessary to incubate
the reaction for longer times, an overnight incubation at 0 "C
being convenient. The type I isozyme of rabbit skeletal muscle
was used for the experiments reported here because it was
found to be more sensitive to cAMP than was the bovine
heart type I1 isozyme under the conditions used. It can be
seen in Fig. 4 that the cAMP level determined using the G25 fractions of hepatocyte extracts was similar whether performed by protein kinase activation assays or radioimmunoassays.
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FIG.3. Assay of cAMP by protein kinase activation at dif-

P

ferent temperatures. The enzyme used was the type I isozyme of
rabbit skeletal muscle. The temperature and times of incubation with
various cAMP concentrations are indicated. Heptapeptide was used
as substrate. Other conditions are statedunder “Methods.”
O’t

01

It

I

I

I

2

I

3

8-pCI+S-cAMP(pM)

FIG.5. Effectof8-pCl@S-cAMPconcentrationon

cAMP
level and phosphorylase. activity in hepatocytes. Hepatocytes
were incubated for 5 min with the indicated concentrations of 8pCl@S-CAMP.Extracts were prepared and processed as described
under “Methods.” G-1 -P, glucose 1-phosphate.

with only a slight change in CAMP.It is known, however, that
small increases in intracellular kinase activity are sufficient
to cause maximal phosphorylase activation in hepatocytes
(21). The CAMP-lowering effect was also seen with several
cyclic nucleotide analogs other than8-pCldS-cAMP (Table I,
0
IO
20
30
Experiments 1 and 2) but not with 5’-AMP (Table I, Experiment 3). A cGMP analog, 8-pCldS-cGMP, also caused lowMINUTES OF HEPATOCYTE INCUBATION
FIG.4. Effect of incubation time on S-pCl@S-cAMP lower- ering of CAMP,but it isknown that cGMP analogs stimulate
ing of hepatocyte CAMPlevels and activation of phosphoryl- cAMP processes in hepatocytes (22). The lowering of cAMP
ase. Hepatocytes were incubated with 1 p~ S-pCl@S-cAMPfor the obtained with cyclic nucleotide analogs was associated in each
indicated times. Extracts were prepared and processed as described case with an activation of phosphorylase.
under “Methods.” cAMP was assayed by radioimmunoassay (RIA)
Effect of CAMP Analogs and Glucagon on Hepatocyte
and by protein kinase activation (PKA)as indicated.
CAMP-The CAMP-lowering effect of 8-pCldS-cAMP was
also obtained when hepatocytes were incubated with relatively
Effect of CAMP Analogs on Basal Hepatocyte CAMP-In
low glucagon concentrations. It can be seen in Table I (Exorder to ensure the absence of trace contaminationof analogs
periment 4) that 0.1 or 0.2 nM glucagon treatment elevated
by CAMP, the analogs were first purified on Sephadex G-25
columns before use in cell incubations. If purified 1 PM cAMP appreciably. These effects were completely blocked or
8-pCldS-CAMPwas added a t zero time to hepatocytes, the nearly completely blocked, respectively, by the addition of 8cAMP level fell by more than 50% (Fig. 4). The effect occurred pCl#S-CAMP.However, when 100 nM glucagonwas used
in 3 min or less, and thecAMP level wasfound to be lowered (Table I, Experiment 3)) which generated very high cellular
using both typesof cAMP assays. Activation of phosphorylase CAMP,the analog did not block the effect. A time course for
the effect of 0.1 nM glucagon in the absence and presence of
occurred parallel with the lowering of CAMP. This result
suggested that the intracellular concentration of 8-pCldS- 8-pC1dS-CAMPis shown in Fig. 6. It can be seen that the
cAMP was sufficient to activate CAMP-dependent protein glucagon-induced elevation in cAMP was transient, the level
kinase, ultimately causing phosphorylase activation. The ef- rapidly increasing during the first 5 min and then declining
fect of 8-pCldS-cAMP to lower hepatocyte cAMP was analog toward the basal value by 10 min. The glucagon-induced
concentration-dependent. It can be seen in Fig. 5 that concen- elevation in cAMP did not occur when 8-pC14S-CAMP was
trations of 0.25 p M or higher of the analog were effective in present. Glucagon caused phosphorylase activation regardless
lowering CAMP. The correlation between the lowering of of whether or not the cAMP analog was present. In the
cAMP and phosphorylase activation was good, except at 0.1 absence of analog, the phosphorylase activity declined slightly
p M analog, where maximal phosphorylase activity was seen after 5 min of incubation.
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TABLEI
Effects of CAMPamlogs and glucagon on hepatocyte CAMP levels
Hepatocytes were incubated for 5 min. One PM cAMP analogs were added. Except where indicated, values are
means of duplicate cell incubations. AHCM-, aminohexylcarbamoylmethyl-;G-1-P, glucose 1-phosphate.
Experiment

cAMP

Phosphorylase

nrnollg tissue

pmol G-I-Pfgfmin

0
8-pCl@S-cAMP
8-Br-CAMP
8-pCl@S-cGMP

0.69 k 0.06 (n = 5)
0.37 f 0.05 ( n = 3)
0.33 f 0.08 ( n 17.5
= 3)
0.44f 0.08 ( n = 3)

7.7
21.3

0
8-NH-benzyl-CAMP
8-Benzyl-S-CAMP
N‘-AHCM-cAMP

0.28
0.15
0.10
0.16

9.9
27.5
25.3
23.8

Addition

1

2

3

0
5”AMP
100 nM glucagon
5.03
100 nM glucagon + 8-pCl@S-cAMP

4

0

8-pCl@S-cAMP
0.1 nM glucagon
0.1 nM glucagon 8-pCI@S-cAMP
0.2 nM glucagon
0.2 nM glucagon + 8-pCl@S-cAMP

+

11.5

0.22
0.23
5.77
0.33
0.19
0.95
0.32
1.18
0.59

be considered as negative feedback and could be beneficial to
the cell by preventing excessive cAMP accumulation. It is
known that cAMP fluctuates over a narrow concentration
25
range in most cell types. If the effect is found to occur with
any hormone which elevates cAMP it would be classified as a
heterologous type of desensitization (6). The transient inGLUCAGON
crease in cAMP by glucagon observed here could be taken as
one line of evidence for a desensitization produced by cAMP
elevation. It has since been found that readdition of glucagon,
after the fall in CAMP,produces a smaller rise in cAMP than
the original (results not shown).
It will be of interest to determine if the CAMP-lowering
effect of cAMP analogs is present in cell types other than
hepatocytes. Mulner et al. (23) recently reported that microin0,80jection of protein kinase inhibitor intoXenopus oocytes causes
an increase in CAMP,which is consistent with our findings.
Fisher et al. (24) observed a rapid (2-3 min) desensitization
9
of 8-adrenergic stimulation of heart cells, which is quantita-0 0.60tively related to cellular CAMP. A CAMP-mediated desensiE
tization was also suggested by the finding of Barovsky et al.
(25) that pretreatment of glioma cells with a cAMP analog
0.40produces refractoriness toward forskolin.
2
The mechanism for the lowering of cAMP by cAMP analogs
is
not clear, although it seems reasonable to assume that it
0.20
G L U C A ~ O N+
occurs through protein kinase activation. The results of a
IpM 8-pCI0S-cAMP
recent comprehensive study of cAMP analog effects on lipolysis and glycogenolysis in adipocytes and hepatocytes, respec1
1
I
I
I
0
5
IO
15
tively, indicated that the analogs are acting by directly stimulating CAMP-dependent protein kinase (9). If protein phosMINUTES OF HEPATOCYTEINCUBATION
phorylation is involved, then the target protein(s) could be
FIG. 6. Effect of 0.1 n M glucagon in the absence and pres- part of either the adenylate cyclase complex or the phosphoence of 1 p~ S-pClbS-cAMP on hepatocyte cAMP and phosphorylase. Extracts were prepared and processed as described under diesterase. Presumably /+receptor phosphorylation is not involved since the cAMP analog effects are obtained in the
“Methods.”
basal state or in the presence of glucagon. Of course, there
may exist cAMP regulation of components of adenylate cyDISCUSSION
clase other than the @receptor. Several groups have also
To our knowledge, the results presented here are the first reported that a hormone-sensitive, low K , phosphodiesterase
reported evidence for control of the hepatocyte cAMP level is activated in adipose tissue (26, 27) and in liver (28-30) by
through protein kinase activation. This type of control might addition eitherof hormones which elevate cAMP or of cAMP

I

GLUCAGON +
IAM 8-pC16S-eAW

f

Y

2

-
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analogs. Since the CAMP-dependent protein kinase is the
only known mediator of cAMP effects in mammalian tissues,
it is reasoned that thisenzyme is responsible for these effects.
One group has reported that the low K,,,
phosphodiesterase
can be phosphorylated by the protein kinase (30). Paradoxically, insulin also activates the same phosphodiesterase even
though this hormone is known to lower cAMP in these tissues
(1, 2, 26-30). Other phosphodiesterases cannot be ruled out
as targets of the cAMP effect. For example, cAMP analogs
could cause an elevation in cellular calcium ion which could
activate acalmodulin-sensitive phosphodiesterase (31). There
are also known to be present cGMP-binding phosphodiesterases (32). It has been suggested, however, that phosphodiesterases are notthe likely target enzymes involved in desensitization processes (7).
Another explanation for the results which should be considered is that the cAMP analogs could compete with endogenous cAMP for the binding sites on the protein kinase. Thus,
activation of the kinase by the analogs might occur parallel
with an increase in free CAMP. Since free CAMP, but not
bound CAMP, is a substrate for phosphodiesterase (33), the
cAMP level could be lowered simply because of higher substrate availability. It might be difficult to distinguish between
this mechanism and a protein phosphorylation reaction since
an increase in free cAMP due to analog competition would be
expected to occur in direct parallel with protein kinase activation.
Perhaps the cAMP analog effects are tissue-specific since
Jarett and Smith(34) found that adipocyte cAMP levels are
actually increased by the addition of N6,02'-&butyryl CAMP.
It was suggested that the increase in cAMP is brought about
by inhibition of phosphodiesterase through competition between the analog and endogenous CAMP. This explanation
for cAMP analog effects has been a dominant viewpoint for
many years. It would be surprising, however, if the effects of
most cAMP analogs on physiological responses are mediated
through rises in cellular cAMP caused by competitive inhibition of phosphodiesterase. In general, the analogs have much
higher affinities for the protein kinase than for the phosphodiesterase (9). At rate-limiting concentrations of analogs, it
wouldbe much more likely that theyareactingthrough
protein kinase activation than through phosphodiesterase
inhibition. In fact, the results presented here indicate that in
hepatocytes the analogs cause a decrease, rather than an
increase, in cellular CAMP.
Acknowledgments-We are grateful to Laura Waynick and Leslie
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